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Abstract
Dysregulation of TNF-a in lamina propria macrophages (LPM) is a feature of inflammatory bowel diseases (IBD). LPS-
Induced-TNF-Alpha-Factor (LITAF) is a transcription factor that mediates TNF-a expression. To determine whether LITAF
participates in the mediation of TNF-a expression in acutely inflamed colonic tissues, we first established the TNBS-induced
colonic inflammation model in C57BL/6 mice. LPM were harvested from non-inflamed and inflamed colonic tissue and
inflammatory parameters TNF-a and LITAF mRNA and protein levels were measured ex-vivo. LPM from TNBS-treated mice
secreted significantly more TNF-a at basal state and in response to LPS than LPM from untreated mice (p,0.05). LITAF
mRNA and protein levels were elevated in LPM from TNBS compared with untreated animals and LPS further increased
LITAF protein levels in LPM from inflamed tissue (P,0.05). To further confirm the role of LITAF in acutely inflamed colonic
tissues, TNBS-induced colonic inflammation was produced in LITAF macrophage specific knockout mice (LITAF mac -/- mice)
and compared to wild type (WT) C57BL/6. Twenty four hours following TNBS administration, colonic tissue from LITAF mac -/-
mice had less MPO activity and reduced colonic TNF-a mRNA then WT C57BL/6 mice (p,0.05). LPM harvested from LITAF mac
-/-secretedsignificantlylessTNF-a inresponseto LPS thanwild type(WT)C57BL/6(p,0.05). This study provides evidencethat
LITAF contributes to the regulation of TNF-a in LPM harvested following acute inflammation or LPS treatment paving the way
for future work focusing on LITAF inhibitors in the treatment of TNF-a-mediated inflammatory conditions.
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Introduction
Tumor Necrosis Factor alpha (TNF-a) is a cytokine that has a
wide variety of functions including immune cell activation and
proliferation.[1,2] TNF-a is produced primarily by macrophages
in response to bacterial byproducts such as lipopolysaccharide
(LPS). Inflammatory bowel diseases such as Crohn’s Disease (CD),
are inflammatory disorders characterized by recurring episodes of
acute colonic inflammation in the gastrointestinal tract.[3] Clinical
and molecular studies have implicated TNF-a as a key mediator in
gastrointestinal inflammatory diseases. The excessive production
of TNF-a can lead to cytotoxicity and tissue damage associated
with inflammation. Anti-TNF-a strategies, including antibodies to
TNF-a, have enabled important advances in the medical
management of CD. Unfortunately, about 30% of patients remain
refractory to current anti-TNF-a antibody therapies,[4,5,6] and
many more must discontinue use due to adverse effects including
infection. Therefore, continued research into new strategies for the
therapeutic regulation of TNF-a action is warranted.
TNF-a gene expression is highly regulated by a complex
promoter region that contains multiple response elements,
including the proinflammatory transcription factor NF-kB.[7] In
1999, Myokai et al. reported the isolation and characterization of a
transcription factor termed Lipopolysaccharide Induced TNF-
Alpha Factor (LITAF), and showed that LITAF plays a role in the
regulation of TNF-a gene expression in a human monocyte/
macrophage cell line (THP-1).[8,9] LITAF was shown to
specifically bind to the CTCCC sequence on the TNF-a promoter
and modulate TNF-a gene expression.[10,11] Stucchi et al. also
reported that both LITAF and TNF-a mRNA and protein levels
are increased in colonic tissue resected from patients with CD and
ulcerative colitis specifically localized to lamina propria macro-
phages (LPM).[12] The presence of LITAF has been confirmed in
mice,[13] and recent evidence has linked increased LITAF mRNA
and TNF-a expression levels in a spontaneous genetic mouse
model of IBD.[14]
Recently, LITAF mac -/- mice were generated using a Cre/
LoxP expression system to specifically target LITAF expression in
cells of the monocyte cell lineage.[15] The purpose of the present
study was to investigate the role of LITAF in the expression and
secretion of TNF-a in LPM harvested from a model of acute
inflammation of the colon. The ex vivo characterization of LPM
harvested from colonic tissue has led to the documentation of
altered properties of LPM following an in vivo inflammatory
stimulus. This study also shows that LITAF contributes to the
increase in TNF-a secretion in macrophages from inflamed
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strategies for the therapeutic management of inflammatory
conditions known to be associated with TNF-a such as IBD.
Materials and Methods
TNBS Induced Colonic Inflammation
Mice were housed in Association for Assessment and Accred-
itation for Laboratory Animal Care-approved facilities and
protocols were approved by the Boston University Medical
Center’s Institutional Animal Care and Use Committee. Exper-
iments were conducted in adult, gender-matched male and female
C57BL/6 mice obtained from Charles River Laboratories
(Wilmington, DE). LITAF mac -/- mice were generated on a
C57BL/6 mouse background using the Cre-LoxP system as
previously described by Tang et. al. [15] Prior to usage in our
experiments, LysMCre-mediated LITAF deletion was confirmed
by PCR and Western blot analyses of lysates of the peritoneal
macrophages harvested by saline lavage. Treated animals were
administered TNBS (BioChemika,1Mi nH 2O) (1.5 mg in 100 mL
of 50% Ethanol/water solution) by enema under isoflurane
anesthesia. Colonic tissue was dissected at 24–72-hours after
TNBS treatment at times associated with acute inflammation in
prior studies.[16,17,18]
Assessment of Colonic Inflammation
Histology. Colonic tissue was dissected and fixed in 10%
formalin prior to being imbedded in paraffin. The paraffin blocks
were then cut into 5 mm specimens and fixed to a slide and then
stained with hematoxylin and eosin using an automated staining
system Sakura Diversified Stainer DRS-601 (Somagen
Diagnostics, Edmonton, Alberta). The histological score of each
tissue sample was assessed by a blinded observer and assigned a
score of 0-4 based on a previously described method [19]. Briefly,
a score of 0 was given if there was no change from normal colonic
tissue. A score of 1 was given if some epithelial hyperplasia and
mononuclear cell infiltrate in a few lesions was observed. A score
of 2 was given if the lesions were more extensive and included
mucus and goblet cell depletion. A score of 3 was given if the
lesions were numerous, extended across large areas of the mucosa,
or into the submucosal layers. A score of 4 was given if the lesions
observed were more severe and most of the colonic tissue was
involved in the inflammation. This includes leukocyte infiltration,
severe epithelial hyperplasia, crypt abscesses and ulcers. Five
sections per mouse were scored; where possible, a section from the
cecum, ascending, transverse, and descending colon and rectum
were individually scored. All histopathological sections were
reviewed by Dr. Michael O’Brien, MD, MPH GI Pathologist.
Myeloperoxidase Activity Assay. Equal weight colonic
tissue sections were completely homogenized on ice using a
Polytron PT-2100 (Kinematica, Inc., Bohemia, NY) in homo-
genization buffer (5 mM phosphate buffer, pH 6.0). Samples
were then centrifuged at 43,000 x g for 30 minutes at 4uC.
Cellular pellets were washed with homogenization buffer and
centrifuged again, as above. Following this wash, the pellet was
resuspended in sonication buffer (50 mM Phosphate Buffer,
pH 6.0 containing 0.5% hexadecyltrimethylammonium bromide)
to a final concentration of 100 mg/mL and sonicated (Sonic
Dismembrator, Fisher Scientific, Pittsburgh, Pa) on ice for 5, 2-
second intervals at full power. Samples were incubated on ice for
20 minutes and then centrifuged for 15 minutes at 12,500 x g at
4uC. To perform the myeloperoxidase (MPO) activity assay,
samples and known standards were allowed to react with assay
buffer (160 mM phosphate, pH 5.4, 30 mM hydrogen peroxide,
10 mM tetramethylbenzidine in water) for exactly 3 minutes
before the addition of the stop buffer (0.66 M sulfuric acid).
Absorbance was read in samples and standards at 450 nm and
milliunits (mU) of MPO were determined.
Lamina Propria Macrophages. Lamina propria macro-
phages (LPM) were harvested from freshly dissected colonic
tissues.[20] Briefly, after the colons were dissected from mice, the
fecal contents and mesenteric tissue was removed and the colon
tissue was cut lengthwise and extensively rinsed with calcium- and
magnesium-free Hank’s balanced salt solution (HBSS; Mediatech,
Inc., Herndon, VA) and then cut into 5 mm long pieces and added
to 50 mL of Digestion Solution I [HBSS with 0.37 mg/mL EDTA
and 0.145 mg/mL dithiothreitol (DTT)]. The tissue was then
vigorously shaken (110 strokes/min) at 37uC (water bath). After
15 min, the media was replaced with fresh Digestion Solution I
(50 mL) for a second incubation. The tissue pieces, which contain
the LPM, were rinsed with 50 mL of HBSS, minced into
approximately 1 mm pieces and added to 20 mL Digestion
Solution II [RPMI 1640 (Sigma-Aldrich, St. Louis, MO), 10%
heat-inactivated fetal bovine serum (FBS) (Invitrogen Corporation,
Carlsbad, CA), 2.5% Antibiotic-Antimycotic (Mediatech, Inc.,
Herndon, VA), 400 U/mL collagenase D (Roche Biochemicals,
Indianapolis, IN) and 0.1 mg/mL DNase type II (Calbiochem,
San Diego, CA)]. The tissue slurry was shaken for 1 hour in a
37uC water bath, and then serially passed through a 1 mm
stainless steel sieve followed by 100 mm disposable sieve (BD
Biosciences, Franklin Lakes, NJ). Cells in the filtrate were washed
twice in HBSS and purified by centrifugation in a 30% percoll
(Amersham Biosciences, Piscataway, NJ) solution diluted in
complete RPMI 1640. The LPM-enriched pellet, confirmed by
cytology to be .98% pure (Diff-Quik and Papanicolaou stain) was
resuspended in complete RPMI 1640 media. The LPM were
incubated at 37uC with 5% CO2 overnight in the appropriately
sized polystyrene dish and non-adherent cells were removed prior
to further treatments. Harvested LPM’s were washed with HBSS
and treated with 1 mg/mL O55:B5 E. coli gel purified LPS
(Sigma-Aldrich, St. Louis, MO) in RPMI 1640 media containing
10% heat-inactivated FBS and 2.5% Antibiotic-Antimycotic for
24 hours. This dose is commonly used for treating monocyte/
macrophages in culture.[21,22] Untreated cells served as control
cells in every experiment. In some ex vivo experiments LPM were
treated with cell signaling inhibitors BAY11-7082 (5 mM) and SB-
202190 (50 nM) 1 hour prior to, and during the course of, LPS
stimulation. Cells were incubated for the indicated time period
before media was collected. Media was pre-cleared by
centrifugation (1000xg) and stored at 280uC until further analysis.
Measurement of TNF-a by ELISA Assay
TNF-a levels in the media were assessed using a mouse TNF-a
ELISA set (BD Biosciences, San Diego, CA) according to the
manufacturer’s instructions. TNF-a concentrations were deter-
mined using a standard and values were normalized to total DNA
present in the well using DNA quantification kit (Sigma-Aldrich,
St. Louis, MO).
RNA Extraction and Quantitative RT- PCR for LITAF and
TNF-a mRNA Levels
Total RNA was isolated from LPM and colon tissue as
previously described using the SV Total RNA Isolation System
(Promega, Madison, WI).[20] Briefly, primary cells were collected
in SV RNA lysis Buffer and added to the provided column
according to manufacturer’s instructions. The RNA samples were
eluted in nuclease-free water and were quantified using a
Nanodrop spectrophotometer. Quantitative real-time reverse
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quantify the mRNA levels of LITAF and TNF-a in isolated LPM.
RT-PCR was conducted with the Gene-Amp RNA PCR System
(Applied Biosystems, Foster City, CA) as described previously [23]
using a DNA Engine DyadH thermal cycler (Bio-Rad, Hercules,
CA). Expression levels were quantified and normalized to the
housekeeping gene b-actin mRNA within each sample as an
internal control prior to further analysis. In addition, a 15 mL
aliquot of the PCR mixture was separated by electrophoresis on a
1.8% agarose gel and stained with ethidium bromide to confirm a
single PCR product.
Western Blotting for LITAF Protein Levels
LPM were washed with HBSS and lysed with M-PER solution
(Thermo Scientific, Rockford, IL) containing protease inhibitor
cocktail (100x). Lysates were sonicated using a Sonic Dismem-
brator (Fisher Scientific, Pittsburgh, Pa), for 10 seconds on ice.
Total protein content in cleared lysates was determined using
BIO-RAD Protein assay (BIO-RAD). Samples were separated
using Invitrogen gels (4–12% Bis-Tris 120 V for 1.5 hours)
transferred to PVDF membranes using 30 V for 1 hour. LITAF
protein levels were detected using a custom made LITAF antibody
generated against the c-terminal region of mouse LITAF
(Biosynthesis, Inc., Lewisville, TX). This antibody was shown
previously to be specific for both human and mouse forms of
LITAF. Blots were then stripped and reprobed for the house-
keeping protein Actin or GAPDH. Optical density of the bands
was determined using Scion image (Scion Corp., Frederick,
Maryland). OD for LITAF levels were normalized to the OD of
housekeeping proteins.
Statistical Analysis
All of the data are expressed as means 6 SEM and were
analyzed by 1-way or 2-way analysis of variance with the Sigma
Stat program (SPSS Inc, Chicago, IL). When significant effects
(p,0.05) were detected, the differences between specific means
were determined by post hoc analysis. In all cases a Dunn test of
analysis of variance by ranks followed by the appropriate
nonparametric post hoc test was used. Groups were deemed to
be significantly different from one another when p,0.05.
Results
Evidence that TNBS Induces Colonic Inflammation
Following TNBS administration, colonic tissue levels of MPO
activity were significantly increased by 24 hours compared to non-
inflamed controls indicating a substantial inflammatory response
(Figure 1A) (p,0.001). Consistent with the use of TNBS to induce
acute colonic inflammation in C57BL/6 mice, the inflammatory
response was markedly reduced on day 2 and 3 compared with
day 1. Histological analysis of colonic tissue 24 hours following
TNBS administration confirmed the severity of the inflammation
and subsequent mucosal damage compared with untreated
animals (Figure 1B). Based on these data, all subsequent ex vivo
experiments utilized LPM harvested 24 hours after TNBS
administration.
Baseline and LPS-Induced Secretion of TNF-a is Increased
in LPM harvested from Inflamed Colons
The baseline secretion of TNF-a into the media was
significantly increased in freshly harvested LPM from inflamed
colonic tissue from TNBS-treated mice compared to LPM from
non-inflamed colonic tissue from non-treated controls (p,0.001)
clearly documenting a change in the properties of the LPM in
response to the inflammatory stimulus (Figure 2A). After 24 hours
of stimulation with LPS (1 ug/mL) ex vivo, TNF-a secretion in
LPM harvested from both inflamed and non-inflamed colonic
tissue was significantly increased (p,0.05) compared with non-
treated controls, but the TNF-a secretion from LPM harvested
from inflamed colonic tissue was .2-fold greater than the TNF-a
secretion from LPM harvested from non-inflamed animals
(p,0.05) (Figure 2A). These data show that the properties of the
LPM have been altered by the in vivo TNBS inflammatory stimulus
such that the ex vivo response to LPS is significantly greater.
LPS Increases LITAF mRNA and Protein in LPM Harvested
from Inflamed Colonic Tissue
LITAF mRNA levels were significantly (p,0.05) increased in
LPM harvested from inflamed colonic tissue and stimulated with
LPS compared to LPM harvested from non-inflamed colonic
tissue (Figure 2B). Although no statistical differences were detected
between LITAF mRNA levels in LPM isolated from inflamed
tissues compared to LPM harvested from normal tissues,
subsequent LPS treatment of LPM isolated from inflamed tissues
did modestly but significantly increase (p,0.05) LITAF mRNA
levels (Figure 2B). LITAF protein levels, determined by western
blot, were also increased 30% (p,0.05) in LPM harvested from
inflamed colonic tissue compared to LPM harvested from non-
inflamed colonic tissue (Figure 3A). In LPM harvested from
inflamed colonic tissue, ex vivo stimulation with LPS induced a 40%
increase (p,0.05) in LITAF protein compared with non-treated
LPM harvested from inflamed colonic tissue (Figure 3B). The
increase in LITAF levels following an inflammatory stimulus
supports the possibility that LITAF plays a role in the increased
TNF-a secretion in these cells.
LPS-Induced Secretion of TNF-a is inhibited by Inhibitors
of p38 and NF-kB from LPM Harvested from Inflamed
Colons
In the context of the potential importance of anti-LITAF
therapeutic approaches we investigated whether an inhibitor of
p38 would reduce the elevated TNF-a response in LPM harvested
from inflamed colonic tissue since p38 signaling pathway is known
to be involved in LITAF activation [15]. LPM treated with the
p38 inhibitor, SB-202190-treated LPM had a significant (p,0.05)
reduction in TNF-a secretion compared to LPS stimulated
DMSO vehicle controls (Figure 4A). SB-202190 had no effect
on TNF-a secretion from LPM not stimulated by LPS.
Additionally, since LITAF is known to bind on sites other than
consensus NF-kB sequences on the TNF-a promoter, we looked
for the role of NF-kB inhibitors in this ex-vivo model. LPM
harvested from inflamed colonic tissue were treated with a NF-kB
inhibitor, BAY11-7082, prior to and during LPS stimulation have
significantly (p,0.001) reduced TNF-a secretion compared to
LPS stimulated DMSO vehicle controls (Figure 4B). BAY11-7082
had no effect on TNF-a secretion from LPM not stimulated by
LPS. These results support the conclusion that TNF-a secretion in
LPM harvested from inflamed colonic tissue is mediated by both
NF-kB and p38 transcriptional pathways.
LPS-Induced Secretion of TNF-a is less in LPM Harvested
from Inflamed Colons of LITAF mac -/- Mice
The deletion of the LITAF gene in LITAF mac -/- was
confirmed by western blot of peritoneal macrophages collected by
peritoneal lavage at time of necropsy and compared to peritoneal
macrophages harvested from a C57BL/6 wildtype mice
(Figure 5A). Peritoneal macrophages were used in lieu of LPM
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due to the limited number of cells obtained from harvesting LPM
macrophages. LITAF deficient LPM harvested from LITAF
mac -/- mice following TNBS administration secrete significantly
less TNF-a (p,0.05) following LPS stimulation ex vivo, than LPM
from wildtype C57BL/6 mice (Figure 5B). These data provide
evidence that LITAF mediates the LPS-induced TNF-a secretion
from LPM harvested from inflamed colonic tissue.
Bodyweight and Colonic Inflammatory Response to TNBS
are less in LITAF mac -/- Mice
In addition to the reduced TNF-a secretory response in LPM
harvested from the inflamed colons of LITAF mac -/- mice, there
were also markedly reduced inflammatory responses to TNBS
administration in vivo. LITAF mac -/- mice lost significantly
(P,0.05) less body weight in response to a 24 hours inflammatory
challenge with TNBS than did their counterpart wildtype C57BL/
6 mice (Figure 6A). Furthermore, following TNBS administration,
colonic samples harvested from LITAF mac -/- mice showed
significantly (p,0.001) reduced MPO levels compared to the
inflamed colons from C57BL/6 mice (Figure 6B). Interestingly,
histological samples taken from LITAF mac -/- mice at 24 and
48 hours following TNBS administration do not show reduced
colonic inflammation overall compared to control C57BL/6 mice
(Figure 7A). Scoring of the histological samples based on
microscopic changes to epithelial layer, crypt depth, edema and
neutrophil infiltration showed no significant overall changes
between C57BL/6 and LITAF mac -/- mice at 24 or 48 hours
following TNBS administration (Figure 7B). Indeed, while the
majority of colonic tissue in both wild-type and knock-out animals
shows only mild inflammation, there is more mucosal damage in
the LITAF mac -/- mice where severe ulceration occurs, with
more neutrophil infiltration, crypt damage, and thickened or
necrotic mucosa due to edema 24 hours following TNBS
administration. At 48 hours following TNBS administration, the
C57BL/6 mice show more signs of tissue repair while LITAF
mac-/- mice still have signs of mucosal and crypt damage in the
ulcerated area. However, colonic samples from LITAF mac -/-
mice following TNBS administration have significantly (p,0.05)
reduced TNF-a mRNA levels compared to inflamed colonic
samples from C57BL/6 mice (Figure 8). These results support that
LITAF mediates TNF-a expression in colonic inflammation but
indicates that TNBS-induced colonic inflammation is a multi-
factorial process mediated by many inflammatory signaling
pathways.
Discussion
The present study demonstrates that LITAF plays an important
role in the regulation of TNF-a secretion in the inflamed colon.
Following a TNBS inflammatory stimulus, LPM harvested from
acutely inflamed colonic tissue secreted higher basal levels of TNF-
Figure 1. TNBS-induced inflammation in C57BL/6 Mice. Inflammation was induced by TNBS (1.5 mg, in 50% ethanol solution) and animals
were monitored for: A) Colonic tissue was collected and assessed for MPO activity (N=4, except Day 1, N=3). Data are expressed as % Day 0 Control
6 SEM.
# Statistical difference (p,0.001). B) Representative histological images of colonic tissue from C57BL/6 mice 24 hours following TNBS
administration showing colonic inflammation (Mag 1006).
doi:10.1371/journal.pone.0025849.g001
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found to further increase this TNF-a secretion. These findings are
further strengthened by our data demonstrating that TNF-a
secretion is significantly reduced in LPM harvested from the
inflamed colons of LITAF mac -/- knockout mice in which the
LITAF gene has been selectively deleted from macrophages. The
present data constitute the first demonstration that LITAF mRNA
expression and protein levels are increased in LPM isolated from
inflamed colonic tissues compared to non-inflamed colonic tissues,
strongly supporting the likelihood that LITAF mediates in part the
increase in TNF-a secretion. Collectively the present data
implicate LITAF in the regulation of TNF-a secretion.
In order to compare macrophage TNF-a secretion responses
following colonic inflammation with and without LITAF, it was
necessary to use C57BL/6 mice because LITAF mac -/- mice
were generated in same strain.[15] Although C57BL/6 mice are
generally resistant to TNBS-induced inflammation[17] it has been
shown that this mouse strain does exhibit a quantifiable
inflammation during the first 24–48 hours following TNBS
administration.[24] This feature of milder degree of inflammation
permitted the isolation of viable LPM for analyses ex vivo. LPM
harvested from inflamed colonic tissue have advantages over
monocyte/macrophage cell lines, such as THP-1 cells, or
macrophages specific to other organs since the specific phenotype
is dictated by the microenvironment in which a macrophage
matures.[25] Primary isolation of LMP also allows for the in vivo
activation of the specific cells which under non-inflamed
conditions show a hyporesponsiveness to LPS.[26] Given the
short duration of the colon inflammation studied (24 hours), it is
highly probable that the LPM harvested are resident LPM and are
not newly recruited monocytes and macrophages whose recruit-
ment to inflamed tissue has been determined to occur from 2 to 10
days following injury.[27]
Inflammatory signaling in macrophages begins with activation
of the Toll like Receptor 4 (TLR4) which leads to activation of
Mitogen Activated Protein Kinase (MAPK) pathways, including
p38.[3] Downstream targets of p38 include numerous transcrip-
tional regulators, including AP-1 and C/EBP-1.[28] In addition,
p38 has been shown to activate LITAF with no significant changes
of TNF-a protein levels in macLITAF
2/2 cells either treated with
LPS alone or cotreated with SB203580 plus LPS.[15] Inhibitors of
p38 were used in this ex vivo system to determine if inhibition could
reduce TNF-a secretion from LPM harvested from inflamed
colonic tissue. A commonly used p38 specific inhibitor SB-202190
[29,30] partially reduces the TNF-a response in LPM harvested
from inflamed colonic tissue following LPS stimulation. While p38
inhibition likely leads to many downstream effects, the observed
reduction in TNF-a secretion is consistent with an inhibition of the
LITAF contribution to TNF-a secretion.
Additionally, TLR4 is known to activate the NF-kB pathway
through the ubiquitination and degradation of IkB. IkB
degradation allows for the translocation of the p65 and p50
heterodimeric unit to the nucleus where transcription of
inflammatory genes, including TNF-a, is induced.[31,32] In this
ex vivo system, inhibitors of NF-kB signaling also caused a
reduction in TNF-a secretion in response to LPS stimulation in
LPM harvested from inflamed colonic tissue. This is not surprising
given that NF-kB is a ubiquitous transcription factor that regulates
Figure 2. Secreted TNF-a levels and LITAF message are increased in LPM harvested from inflamed colonic tissue compared to LPM
harvested from non-inflamed colonic tissue. A) Following TNBS administration, LPM were harvested and stimulated with LPS (1 ug/mL) ex vivo
(24 hours) and TNF-a secretion was measured (N=8). Data are presented as % Non-Inflamed Non-treated control 6 SEM. * Statistical difference
(p,0.05), # statistical difference (p,0.001). B) LITAF message levels are increased in LPM harvested from inflamed colonic tissue following LPS (1 ug/
mL) stimulation (1 hour) compared to LPM harvested from non-inflamed colonic tissue (N=7 for Non-treated, N=8 LPS treated). Data were
normalized to b-Actin message and presented as % Non-Inflamed Non-treated group 6 SEM. * Statistical difference (p,0.05).
doi:10.1371/journal.pone.0025849.g002
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following LPS (1 ug/mL) stimulation (N=5). A) Western blot of LITAF levels and GAPDH levels in freshly harvested LPM from Non-Inflamed and
Inflamed colonic tissue. The graph shows the optical density (OD) of LITAF levels normalized to GAPDH levels. * Statistical difference from Non-
Inflamed group (p,0.05). B) Western blot of LITAF levels and b-Actin levels in LPM harvested from inflamed colonic tissue stimulated with LPS ex vivo
compared to LPM harvested from inflamed colonic tissue, but not treated with LPS (Non-treated). The graph show OD of LITAF levels normalized to
b-Actin levels. * Statistical difference (p,0.05).
doi:10.1371/journal.pone.0025849.g003
Figure 4. Secreted TNF-a levels from LPM harvested from inflamed colonic tissue are reduced with the administration of signaling
inhibitors. A) Secreted TNF-a from LPM harvested from inflamed colonic tissue are reduced when administered p38 inhibitor (SB-202190) prior to,
and throughout LPS (1 ug/mL) stimulation (24 hours) (N=8). Data are expressed as % Inflamed DMSO vehicle 6SEM. * Statistical difference (p,0.05),
# statistical difference (p,0.001). B) Secreted TNF-a from LPM harvested from inflamed colonic tissue are reduced when administered NF-kB inhibitor
(BAY 11-7082) prior to, and throughout LPS (1 ug/mL) stimulation (24 hours) (N=6). Data are expressed as % Inflamed DMSO Vehicle group 6 SEM.
# Statistical difference (p,0.001).
doi:10.1371/journal.pone.0025849.g004
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harvested from C57BL/6 mice. A) Western blot of LITAF and Actin confirming the knockout of LITAF protein in peritoneal macrophages harvested
from LITAF mac -/- and C57BL/6 mice. B) TNF-a secretion from inflamed LPM isolated from colonic tissues of LITAF mac -/- (N=6) or wildtype C57BL/6
(N=12) following LPS stimulation (24 hours). Data are expressed as % Inflamed C57BL/6 group 6 SEM. * Statistical difference (p,0.05), # statistical
difference (p,0.001).
doi:10.1371/journal.pone.0025849.g005
Figure 6. LITAF macrophage specific knockout mice (LITAF mac -/-) show reduced changes in bodyweight and MPO following TNBS
administration. A) Following TNBS (3.0 mg) administration to LITAF mac -/- mice (N=6) and C57BL/6 mice (N=6), bodyweights were measured
24 hours later. Data are expressed as % initial (day 0) bodyweight. * Statistical difference (p,0.05), # statistical difference (p,0.001). B) Following
TNBS (3.0 mg) administration to LITAF mac -/- mice (N=6) and C57BL/6 mice (N=6), colonic tissue was collected and assessed for MPO activity. Data
are expressed as % Non-inflamed MPO activity.
# Statistical difference (p,0.001).
doi:10.1371/journal.pone.0025849.g006
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and cancer.[32,33,34] The human TNF-a promoter region
contains multiple NF-kB consensus sequences, in addition to
consensus sequences for many other transcription factors,
including SP-1 and Erg1,[35] NF-AT,[36] AP-1 and AP-2,[37]
CREB/ATF,[38] and Ets.[39] Although not definitive, taken
together, our data lend support to our hypothesis that the
increased TNF-a response in LPM harvested from inflamed
colonic tissue may stem from multiple pathways including NF-kB,
LITAF and p38 MAPK pathways.
The most direct evidence that LITAF is associated with the
capacity of LPM to secrete TNF-a comes from the use of LITAF
deficient LPM in these studies. Using LPM harvested from LITAF
mac -/- mice following TNBS induced inflammation, the data
supports the conclusion that the deletion of the LITAF gene leads
to a significant reduction in TNF-a secretion in response to LPS
stimulation compared to wildtype controls. Since differences in
TLR4 mRNA levels were not found between peritoneal
macrophages derived from C57BL/6 and LITAF mac -/- mice
(data not shown) it very likely that this process is not dependent on
changes in TLR4. In this system, the remaining TNF-a signal that
we have observed in LITAF deficient macrophages is likely due to
the remaining proinflammatory pathways including NF-kB.
LITAF mac -/- mice exhibit reduced bodyweight loss, have
lower MPO levels and, on examination of their colonic tissue,
express less TNF-a mRNA as compared to C57BL/6 mice.
Despite the apparent reduction in the acute TNBS-induced
inflammatory response, LITAF mac-/- mice do not exhibit a
reduction in the overall histological damage to the colonic tissue
following 24 or 48 hours after TNBS administration. These
findings suggest that the animals deficient in LITAF have a
delayed healing response compared to C57BL/6 mice. This may
Figure 7. TNBS-induced histological damage is not reduced in LITAF mac -/- mice. A) Representative histological images of colonic
inflammation: Untreated Control; TNBS 24 hours; and, TNBS 48 hours following TNBS administration. (N=3) images (Mag 1006). B) Histological score
(0–4) 6 SEM (N=5) of colonic tissue 24 and 48 hours following TNBS administration.
doi:10.1371/journal.pone.0025849.g007
Figure 8. TNF-a message levels from inflamed colonic tissue
harvested from LITAF macrophage specific mice (LITAF mac -/-
mice) is reduced compared to C57BL/6 mice. TNF-a message
levels were measured in colonic tissue following TNBS administration
(0.3 mg) for 24 hrs in LITAF mac -/- mice (N=6) and C57BL/6 mice
(N=12). Data are expressed as % Non-Inflamed control 6 SEM.
* Statistical difference (p,0.05).
doi:10.1371/journal.pone.0025849.g008
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TNBS administration imparts when administered rectally. Anoth-
er explanation for this result may be related to a beneficial
dysregulation of the inflammatory response in LITAF mac -/-
animals.[15,40] Indeed LITAF mac -/- mice have been shown to
have reduced levels of many inflammatory cytokines and
chemokines, when administered a sublethal dose of LPS.
Compared to the early surge of serum inflammatory cytokines
seen in wildtype mice, LITAF mac -/- mice show a delayed
increase of proinflammatory cytokines, and a persistent increase of
anti-inflammatory cytokines illustrating that the absence of LITAF
leads to a beneficial temporal dysregulation of the inflammatory
response.[15,40] The histological inflammatory response observed
24 hours after the acute inflammatory stimulus of TNBS in
LITAF mac -/- mice may just reflect a delay of inflammation
consistent with the previous report [15,40].
Interestingly, while making synthetic derivatives of the lactone
kavain, Pollastri et al. identified an acyclic derivative ((E)-5-
biphenyl-4-yl-5-hydroxy-3-methoxy-pent-2-enoic acid methyl es-
ter) and showed this compound to suppress LITAF levels while
simultaneously reducing TNF-a secretion from macrophages
stimulated with LPS.[41] Future studies may lead to optimization
of this compound and may increase our understanding of the
feasibility of the use of kava compounds to specifically inhibit
LITAF and further explore anti-LITAF strategies as a potential
treatment for inflammatory diseases known to be associated with
increased TNF-a.
In summary, endogenous colonic LPMs increased their base
line and LPS mediated TNF-a secretion by a LITAF dependant
pathway when harvested from acutely inflamed colonic tissue
suggesting the usefulness of anti-LITAF drug development for the
treatment ulcerative colitis. We propose that LITAF plays a
substantial role in TNF-a secretion from LMP isolated from an
acutely inflamed colon and represents an alternative pathway to
modulation of the TNF-a component of the inflammatory
response. A better understanding of the role that LITAF signaling
plays in regulating TNF-a gene expression in the LPM of the
inflamed colon may provide alternative targets for therapeutic
interventions not only in IBD, but other chronic inflammatory
diseases exacerbated by elevated TNF-a levels.
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